A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20007, United States
Worcester, Massachusetts 01655-0138, United States
New York, New York 10019, United States
Winston-Salem, North Carolina 27157, United States
Henningsdorf, 16761, Germany
Seesen/Harz, 38723, Germany